univers coverag
calendar event
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
outperform market cap price price target methodolog dcf
discount rate termin growth rate
bottom line initi coverag crinet outperform rate
price target crinet clinic stage biotechnolog compani build rare diseas franchis
endocrinolog view compani pipelin oral non-peptid drug candid target protein-
coupl receptor gpcr posit peptide-bas drug tradit safe
effect crinet strateg aim take advantag shortfal develop conveni daili
oral non-peptid formul potenti improv toler efficaci may translat
signific market penetr expans especi encourag experienc management
team lead program leverag chemistri biolog expertis three indic
peptid somatostatin sst analog either approv use off-label
believ crinet lead program could showcas experienc management team chemistri
biolog expertis
believ even base case scenario -- oral drug food effect similar efficaci
approv pain inject drug -- could win
behind crinet two program could de-risk diversifi compani endocrin platform
 valu includ estim
dcf analysi revenu multipl dr tgr
bottom line initi coverag outperform rate
price target differenti preclin stage cell therapi compani develop red
cell therapi consist genet engin red blood cell express therapeut protein
within surfac cell number potenti advantag cell therapi
platform base red blood cell includ off-the-shelf approach potenti broad
therapeut applic rare diseas oncolog autoimmun diseas howev still
number develop risk point given earli stage develop first ind file expect
acknowledg valuat method signific shortcom earli
stage clear us swing fenc type play approach uniqu
differenti could potenti transform cell therapi field success addit
view well posit execut strategi highli experienc manag team
strong financi posit overal posit long-term view stock
advantag cell therapi platform base red blood cell
platform potenti broad applic rare diseas oncolog autoimmun
posit execut strategi
leadership seri growth momentum sustain stemi data
ev/sal multipl estim
bottom line last week august host leerink med-tech leadership seri call
ceo mike minogu cfo todd trapp director ir ingrid goldberg ward
tone call upbeat reinforc view recent share weak overdon present
opportun long-term investor manag frame larg under-penetr market
opportun cardiogen shock high-risk pci percutan coronari intervent
hold monopoli manag clearli target penetr
patient grow popul vs penetr today overal came away encourag
strong double-digit long-term growth trajectori beat rais stori sustain
forese futur importantli call reinforc view sale growth
guidanc prove conserv beatabl street
top-end guidanc rang y/i growth manag note desir
prudent conserv given one quarter year fundament
perspect real reason see meaning step-down growth
progress year outsid typic season summer month still
signific runway growth highli under-penetrated multi-billion dollar market opportun
peg current penetr rate total current address market
patient germani begin japan stemi
st-segment elev myocardi infarct feasibl data releas -- expect american
heart associ aha chicago novemb -- next major catalyst
stock given indic would repres next leg growth doubl
though data hand manag couldnt comment trial base
littl manag could say seem adopt posit spin
potenti viabil stemi market clear strateg plan knock
educ technolog barrier still exist impella adopt continu
train physician build clinic data evolv product built competit
moat around impella signific patent protect around key ease-of-us featur like
pigtail cathet viabl competit near even mid-term sight oper
margin end rang manag offici
provid guidanc note room move even higher still
goodby price hello valu propos rule posit
bottom line thursday center medicar medicaid servic
introduc propos rule pathway success seek overhaul account
organ aco medicar share save program mssp forc faster
transit dual-sid risk particip current law aco oper mssp
year without take downsid risk still abl receiv payment
effect control cost propos rule shorten grace period
two year forc aco take downsid risk wish receiv bonu payment
addit propos reduc number aco track two
three increas level risk aco take two track project
aggreg effect propos would save medicar year
secretari seema verma explain remain commit drive shift
value-bas care commit use everi tool dispos move
health care system toward value-bas care prioriti
leadership secretari presid trump entir administr align toward
achiev goal highli encourag rule secretari verma comment
show continu support push acceler shift value-bas care believ
propos rule lead increas demand popul health vendor
evol op mp premier op qualiti system qsii mp
reduct two track propos
rapid shift two-sid risk like increas demand trust popul health partner
propos rule also promot adopt certifi ehr
project propos rule save year
link seema verma summari affair link
link rule link
link factsheet link
recent fda industri appoint posit next-gen
bottom line want highlight two recent key appoint fda lead
clinic center worth note view posit uptak next-gen
sequenc importantli deriv revenu clinic market
dr timothi stenzel appoint director fda offic vitro diagnost
radiolog oir dr gianrico farrugia appoint ceo mayo clinic
physician scientist strong experi base genet test dr stenzel recent
invivoscrib cdx companion diagnost oncolog focus compani
believ appoint posit speak eventu goal make genom part
routin clinic care highlight geising may announc see benefit
op current ion torrent platform longer term see agil op lasergen cdx platform
also posit well fda increasingli recogn grow role diagnosi treatment
evolv toward genom part routin clinic care
believ recent appoint help drive genom toward routin clinic care
exposur clinic market increas
geising releas may link
bottom line increas convict ebitda growth margin expans
opportun rais pt beat meet manag ceo cfo
head strategi compani nashvil headquart aug physician
recruit advantag independ natur compar
peer scale resid either hospit umbrella per manag
opportun musculoskelet remain substanti translat continu favor
mix shift price growth manag focus grow total ebitda part margin
expand given oper improv favor growth opportun view
expand margin bp annual categor three bucket across
organ growth case volum price case mix shift revenu cycl manag market
growth new partnership fit growth bucket improv oper infrastructur
size scale bucket focus high growth specialti orthoped spine
proof point strategi guidanc reiter ebitda beat solid price
mix acuiti volum soft encouragingli improv qoq impact divestitur
closur manag reassess portfolio focu core opportun remain
lever view ebitda growth leverag reduc year-end
maintain ebitda mm mm mm respect
link recent initi
increas convict post meet manag nashvil headquart aug
manag remain focus long-term prospect volum growth though
disrupt short term reorgan effort prune asset
invest physician recruit retent drive volum mix higher acuiti servic
privat payor mix improv yoy focu increas acuiti drive solid price
improv contract payor partnership drive volum higher acuiti procedur
unlock valu current portfolio asc manag improv procur
creat scalabl platform expand exist facil relationship
rebuild pipelin strateg assess asset fit core growth
proof point revenu ebitda beat
remain lever view ebitda growth leverag reduc
year-end
rais pt
revenu million ep adjust dilut
bottom line cymabay healthi balanc sheet cash drive seladelpar
avenu growth primari biliari cholang pbc nonalcohol steatohepat
nash nash studi initi pbc studi on-deck initi well
updat enrol progress well addit detail eg pbc studi child pugh b/c
pt expect futur reiter op pt
ceo hit strateg reset button reduc rev/ep outlook pt
bottom line reiter mp rate expect elgx share weak -- despit in-
line result -- given significantli lower rev/ep outlook elgx new ceo hit reset
button base revamp go-to-market strategi underli intra-qtr busi trend
management lower rev/ep guidanc midpoint continu think us
afx soft weak nellix sale serv extend overhang stock management
demonstr progress turn around franchis ceo onopchenko
take step improv commerci organization/strategi wait-and-se execut stori
view near-term elgx bigger catalyst growth re-acceler still weight
see rush share pt goe vs prior lower
estim reflect new cash/debt balanc follow elgx debt restructur
revenu mm ep adjust item
discount rate termin growth rate
bottom line remain encourag resum clinic trial look
forward intermedi day biopsi data may report atyp quarter
sinc head fda place compani lead gene therapi program
duchenn muscular dystrophy/dmd clinic hold march link get lift
june link compani guid interim data link encouragingli compani
abl obtain intermedi muscl biopsi day could signal efficaci assum
exercis option work make lost time especi op
program current clinic hold due contamin issu link could take advantag
look forward updat link compani end quarter cash/cash
equival reiter outperform
weekli iqvia im trend week end august
bottom line note analyz iqvia formerli im script trend week end august
harvoni epclusa vosevi mp mavyret mp zepati nr
hcv genvoya descovi odefsey biktarvi juluca gsk nr hiv tagrisso azn
nr lung cancer imbruvica abbv/jnj op zydelig venclexta abbv/rhhbi nr
hematolog malign ibranc nr kisqali nv nr verzenio nr breast
cancer xtandi zytiga prostat cancer cabometyx nr renal cell carcinoma
otezla celg op plaqu psoriasi psoriat arthriti cosentyx nv plaqu psoriasi
psoriat arthriti ankylos spondyl taltz plaqu psoriasi tremfya plaqu
psoriasi dupix sni nr/regn op eucrisa atop dermat kevzara sny/regn
rheumatoid arthriti tecfidera mp multipl sclerosi breo anoro incrus trelegi
gsk/inva nr chronic obstruct pulmonari diseas nucala gsk fasenra azn
asthma praluent sny/regn repatha mp entresto nv cardiovascular diseas
trulic jardianc basaglar toujeo soliqua sni tresiba xultophi ozemp
nvo nr diabet austedo teva huntington contrav orex nr obes ocaliva
mp primari biliari cholang intrarosa mp dyspareunia actemra rhhbi
immuno-oncolog aimovig migrain
pleas see bodi report detail weekli iqvia script
anim health steadi dental weigh turn-around take time initi
mp
summari leerink west coast biotech bu tour day
newsflow check vertic deal meaning rais odd close
nc open busi releas medicaid manag rfp
rebat retent modest esrx pbm add signific valu regardless
continu believ vertic merger gain approv state minim
recap eye decemb data readout follow strateg
outperform market cap price price target methodolog dcf
ci show limit rebat impact esrx move aug vote toward
recap fop mo program track dri indic soon enter
initi doptelet sale boost channel build catalyst still year away
 methodolog dcf discount rate termin valu
recap groundwork continu complement expans
analysi use discount rate termin growth rate convert impli market cap
eur usd use month fx averag /em
refocus back consum healthcar root pt
 methodolog sum-of-the-part weight average ev/ebitda multipl
recap doubl tripl data
outperform market cap price price target methodolog dcf
use discount rate termin growth rate
recap casi- take pg golo- playbook updat
dcf discount rate termin growth rate
sale
dmd catalyst come huntington loom
thesi base continu captur cystic fibrosi cf patient subpopul
vertex success iter cf modul oral combin medicin
multipl near-term catalyst approach link
august look fda approv kalydeco treat cf infant
month age follow approv age
later anticip multipl develop includ
phase result kalydeco cf infant month age
ema approv symdeko treatment homozyg patient
phase result symdeko cf children age year old
eu approv orkambi treat homozyg patient year age
also expect initi phase i/ii trial treatment beta thalassemia
europ sickl cell diseas respect
one regn import catalyst approv antibodi cemiplimab
cutan squamou cell carcinoma cscc
compani pdufa date octob research suggest first approv
checkpoint antibodi new indic typic come ahead pdufa date like
june juli cemiplimab estim
particularli true applic benefit breakthrough design
prioriti review case cemiplimab
regeneron also appear signal expect approv occur earlier
date confirm us commerci team readi launch product
immedi avail channel
project peak pos-adjust us cemiplimab sale
aug ci sharehold vote esrx merger
ci-esrx deal seen pro-competit manag regulatori risk although
potenti activist activ involv deal see link note
view sharehold vote import binari event expect ci stock trade
vote unsuccess
accord wall street journal carl icahn own less ci stock
plan vote deal link link link
howev remain skeptic sharehold vote deal absent anoth
credibl well-capit buyer ci link link
ci manag indic esrx best capit deploy opportun ci drive
afford better outcom across broad payor mix ci estim
synergi deal success see link ci meet analysi
link analysi link
continu view ci deep valu name patient investor combin
mid-august hire extern sale rep cologuard screen
cologuard highli under-penetr strong popul need
colorect cancer screen believ could deliv penetr
revenu longer term penetr ttm sale
recent analysi util leerink healthcar advanc analyt suggest
hire extern rep remain track complet mid-august earlier
timelin highlight
view revenu growth depend fast compani hire sale rep
particularli extern rep harder find hire intern one
turn drive new physician reorder catalyz growth exist physician order
rep hire faster abl reach new pcp aggress
abl serv exist account sooner and/or frequent -- ultim drive upsid
estim take month rep becom fulli product
result updat like earli august
believ investor expect head ph data readout
low especi sinc lack clariti around requir approv
still discuss fda around data analysi plan studi
niemann-pick type np-c ultra-rar progress neurodegen genet
diseas occur bodi properli break cholesterol lipid
lead harm amount lipid accumul spleen liver brain
believ ph i/ii result encourag given breakthrough
statu drug fda prior comment bar approv like low
medacorp specialist spoke enthusiast current
treatment altern off-label use miglustat limit efficaci high ae
rate diarrhea abdomin pain nausea
forecast sale grow larg opportun
believ one sever pipelin asset critic offset
declin key franchis acthar inomax ofirmev face competit
come year posit regulatori execut increas investor
interest emerg pipelin
call announc earlier-than-expect complet enrol
follow-up stemi short-term elev myocardi infarct feasibl studi
put data present like aha chicago pivot trial start
possibl earli time-frame sooner base estim
esposito et al publish result anim studi jacc support left
ventricular unload prior reperfus translat human would impli impella
success stemi reduc infarct size prevent late-stag onset
heart failur -- someth would clinic relev also cost effect
concurr editori jacc review clearli bullish implic
esposito studi potenti impella use stemi patient outcom
reproduc human primari mechan lv unload enorm benefit
reduc futur hf event patient acut mi note intervent cardiologist
may also need prepar modifi therapeut strategi mi
estim stemi year would
doubl exist address patient popul high risk pci cardiogen
believ data present american psychiatr associ confer
provid limit insight genesight endpoint
view test key mygn long-term top-lin growth potenti
drive revenu upsid reimburs mygn desir
current medicar rate
signific controversi alreadi surround reach potenti given
pt trial fail meet primari endpoint met secondari endpoint remiss
respons data may provid sub-
analysi patient fail chang view medacorp specialist payer
journal public expect june coverage/contract decis expect
announc beyond
link takeaway meet manag
regulatori settlement behavior health feder state agenc appear like
posit catalyst
negoti remain on-going manag optimist settlement reach
investig state feder regul year
settlement reserv increas pre-tax
sourc leerink research compani inform factset price prior day
medcac panel t-cell therapi
fda public hear biosimilar silver spring md
pdufa teva fremanezumab cgrp migrain
fda adcom vaccin relat biolog product
pdufa dupix moder sever asthma adult adolesc
pdufa xyrem cataplexi excess daytim sleepi
pdufa revefanacin lama copd
pdufa bremelanotid hypoact sexual desir disord fda adcom
schedul
world congress cancer skin
european societi cardiolog esc
associ offici analyt chemist aoac
societi laparoendoscop surgeon minim invas surgeri week
intern network fatti acid oxid research manag
world congress pharmaci pharmaceut scienc fip
societi studi inborn metabol diseas ssiem symposium
bioprocess intern confer exhibit
advanc genom biolog technolog agbt precis meet
societi minim invas spine surgeri smiss annual forum
american societi hypertens joint w/ american heart associ aha
european migran headach trust intern congress ehmtic
american academi otolaryngolog head neck surgeri aao-hnsf
intern societi research iser biennial meet
intern associ studi pain iasp world congress pain
european academi dermatolog venereolog eadv
american societi surgeri hand assh
advanc genom biolog technolog agbt precis meet
associ vascular access annual scientif meet
heart failur societi america hfsa annual scientif meet
deadlin lpnt solicit altern acquisit propos
go live az
model model achn cmta dova elgx ifrx
pti recent updat pleas contact leerink
repres wish review
 takeaway immuno-oncolog panel
 takeaway nash panel
biopharma lp hic takeaway ibd panel
 takeaway migrain panel
biopharma lp hic reimburs panel oncolog gene therapi target limit
 rova-t present show anoth rout failur experiment oncolog
adap -- flash manag convers highlight data pipelin progress
adap studi advanc cell dose posit safeti data pt
-- flash present highlight opportun colorect cancer
celg updat strengthen profil remark respons durabl
celg profil continu present outperform
 tazemetostat mesothelioma data opportun combin outperform
 success pamrevlumab lapc may depend endpoint paradigm shift
imdz -- flash event highlight imdz approach strategi outperform
 event highlight investig view forward ii data outperform
-- flash highlight encourag data biomark strategi gastric
-- flash updat demonstr continu safeti earli efficaci
 half full half empti alzheim diseas puls call takeaway market perform
 ctad medacorp call aducanumab abeta hypothesi
biopharma biopharma catalyst tracker import catalyst remain second half
 takeaway annual day
 biotech portfolio concentr explain multipl compress
 first apprais tax offer small benefit
 vertex alexion top pick
-- flash takeaway leerink day outperform
 eas data confirm durabl gocovri superior vs gener
 day preview late stage program turn launch mani
 takeaway annual day
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
 growth deal capac target market
biopharma praluent show mortal benefit lower take aim highest risk group
mdco -- flash inclisiran lesson fourier/odyssey may better
novob dc highlight nvo management roundtabl discuss boston market
medic devic ada dash make splash highlight recent
medic devic leerink healthcar confer panel devic penetr set
medic devic leerink leadership seri outset drive shift dialysi self-car
novob dc highlight nvo management roundtabl boston market perform
medic devic leerink healthcar confer panel devic penetr set
medic suppli devic initi takeaway sage robot continu gain
medic devic survey support market share re-gain assumpt
medic devices-cardiolog hr takeaway cabana unlik chang af practic
biopharma price right payer fail get drug class come
 stabil sell-sid price trend medic posit ug op outperform
hcit distribut fda take step improv competit distributor near trough
 acthar survey suggest faster eros payer pressur competitor entri
qure updat model higher price assumpt po pt
 price commerci updat fda approv burosumab/crysvita
 respit price yet friendli hill fda could
biopharma trump-azar puls call drug price blueprint limit current hh
 hemophilia price adjust reflect efficaci luxturna paradigm pt
 outlook move higher price clariti suggest possibl upsid pt
hcit distribut blueprint thorough pbm like abl manag rebat
hcit distribut outlin possibl drug price polici draconian
fear
 updat hemophilia price assumpt ad pomp program pt
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc outperform
celg qed ged late stage failur throw ibd bd strategi
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
 patent strategi come focu mitig biosimilar risk outpfrm outperform
 news patent decis one remind method use patent
 doubl extend patent horizon tecfidera
 investor sleep path ip protect pt
adap kol address controversi ahead multipl data readout outperform
 anoth setback ido outperform ideal combo still unclear
biopharma what immuno-oncolog takeaway
biopharma summari leerink immuno-oncolog roundtabl
celg anoth bet car-t probabl probabl sensibl even
 deep dive highlight oncolog focu strategi nash market perform
 highlight kol panel lung cancer io cell
celg anoth bet car-t probabl probabl sensibl even
biopharma might deton event look like screen pot match-
 sotp support current stock price where pipelin upsid market
 sotp suggest pipelin free even stock bounc market perform
 dupi miss-inventori demand trend intact partnership flail
biopharma viii partnership acquisit biopharma new top list
ci june ci cfo boston meet insight rais pt outperform
 aet bring comprehens member
dplo mid-mkt pbm acquisit complet strateg move market perform
esrx detail esrx deal term dplo may acquisit target
 evolv provid landscap initi outperform initi
outperform
 partnership valid local jaki gut de-risk develop path pt
 increas pt takeda collabor stock weak offer oppti
manag -- flash gov lose t-twx close without condit posit
pharmaci benefit manag t-twx approv bode pend ci-esrx cvs-
outperform
deal capac
-- contact leerink repres detail access podcast
 pnh survey-soliri still grow like switch monthli sc best
athn survey highlight slow market time take deal pt market
biopharma atop derm still without ped leerink dupi derm survey
 hiv survey rapid adopt biktarvi challeng outlook
hcit distribut ambulatori survey show slowdown replac market on-going
shift vbc
 vyxeo survey suggest outpati usag grow outperform
major medacorp survey lung cancer posit azn
medic devices-cardiolog tavr survey in-lin out-year trend quarter look
ew thv link link
medic suppli devic survey suggest may wait
medic devic survey support market share re-gain assumpt
 acthar survey suggest faster eros payer pressur competitor entri
 bone pick medacorp survey suggest solid crysvita adopt esp
medic devic survey direct posit mute hope
teva rais austedo sale analysi posit medacorp physician survey
-- flash leadership seri growth momentum sustain stemi data
 open ablat atriclip drive near term growth mi longer term
 differenti poc signific runway impli upsid pt
 ceo call focus growth outlook potenti upsid area lrp pt
outlook alpha opportun abound healthcar share
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight heart failur kol discuss
